ZIM Laboratories Limited (NSE:ZIMLAB)

Market Cap	3.60B -10.4%
Revenue (ttm)	3.78B -2.7%
Net Income	69.83M -54.6%
EPS	1.43 -54.4%
Shares Out	n/a
PE Ratio	51.57
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,462
Average Volume	88,060
Open	66.80
Previous Close	67.47
Day's Range	65.26 - 69.00
52-Week Range	59.31 - 127.00
Beta	0.47
RSI	52.45
Earnings Date	May 22, 2026

About ZIM Laboratories

ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, granules, tablets, capsules, dry syrup, and oral thin films. The company offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1984
• Employees: 577
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ZIMLAB

Financial Performance

In fiscal year 2025, ZIM Laboratories's revenue was 3.79 billion, an increase of 3.16% compared to the previous year's 3.68 billion. Earnings were 121.65 million, a decrease of -29.46%.